Mostrando 10 resultados de: 14
Filtros aplicados
Subtipo de publicación
Article(14)
Publisher
Canadian Journal of Cardiology(2)
Gastroenterology(2)
New England Journal of Medicine(2)
Stroke(2)
The Lancet(2)
Área temáticas
Enfermedades(13)
Medicina y salud(10)
Farmacología y terapéutica(5)
Fisiología humana(2)
Problemas sociales y servicios a grupos(2)
Área de conocimiento
Enfermedad cardiovascular(9)
Medicina interna(7)
Medicamento(3)
Cáncer(1)
Epidemiología(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(14)
ODS 3: Salud y bienestar(14)
ODS 17: Alianzas para lograr los objetivos(12)
ODS 1: Fin de la pobreza(1)
ODS 9: Industria, innovación e infraestructura(1)
Origen
scopus(14)
Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study
ArticleAbstract: Background There are few data on heart failure (HF) patients from Africa, Asia, the Middle East andPalabras claves:epidemiology, Global Health, Heart Failure, registryAutores:Alhabib K.F., Badr A., Balasubramanian K., Belley-Cote E.P., Damasceno A., Dokainish H., Elmaghawry M., ElSayed A., Grinvalds A., Harkness K., Huffman M.D., Karaye K.M., Lanas F., McKelvie R., Mondo C.K., Orlandini A., Palileo-Villaneuva L., PATRICIO LOPEZ -JARAMILLO, Prabhakaran D., Roy A., Sliwa K., Teo K.K., Tibazarwa K., Yacoub M.H., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusFixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis
ArticleAbstract: Background: In randomised controlled trials, fixed-dose combination treatments (or polypills) have bPalabras claves:Autores:Avezum A.J., Bangdiwala S.I., Bosch J.J., Castellano J.M., Dagenais G.R., Dans A.M., DIaz R., Fuster V., Gamra H., Gao P., Huffman M.D., Joseph P.G., Liu L., Lonn E.M., Malekzadeh R., Pais P., PATRICIO LOPEZ -JARAMILLO, Prabhakaran D., Rodgers A., Roshandel G., Sliwa K., Teo K.K., Xavier D., Yusuf S., Zhu J.Fuentes:googlescopusBlood-pressure and cholesterol lowering in persons without cardiovascular disease
ArticleAbstract: BACKGROUND Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase tPalabras claves:Autores:Accini J.L., Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., McKelvie R., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusBlood-pressure lowering in intermediate-risk persons without cardiovascular disease
ArticleAbstract: BACKGROUND Antihypertensive therapy reduces the risk of cardiovascular events among high-risk personPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., McKelvie R., Molina D.I., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Wilkinson J., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusBleeding and New Cancer Diagnosis in Patients With Atherosclerosis
ArticleAbstract: BACKGROUND: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be thePalabras claves:aspirin, hemorrhage, neoplasms, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Connolly S.J., Cook-Bruns N., Eikelboom J.W., Felix Camilo, Fox K.A.A., Hart R.G., Maggioni A.P., Moayyedi P., O’Donnell M., Rydén L.E., Shestakovska O., Verhamme P.B., Widimsky P., Yusuf S., Zhu J.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusNovel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
ArticleAbstract: Background: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Fodor G.J., Held C., Jansky P., Keltai K., Keltai M., Kim J.H., Kunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy
ArticleAbstract: Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not knownPalabras claves:aspirin, COGNITION, infarction, rivaroxaban, white matterAutores:Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Branch K.R.H., Casanova A., Connolly S.J., Dagenais G.R., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Fox K.A.A., Hart R.G., Keltai K., Keltai M., Kim J.H., Liang Y., Liu L., Lonn E.M., Maggioni A.P., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Reeh K.W., Rydén L.E., Sharma M., Smith E.E., Störk S., Tonkin A.M., Varigos J.D., Vinereanu D., Yusuf S., Zhu J.Fuentes:googlescopus